close
Add to watchlist
AstraZeneca ADR (AZN) Healthcare, Major Drugs
AstraZeneca plc discovers, develops, manufactures, and markets prescription pharmaceuticals and biological products in the areas of cardiovascular, gastrointestinal, neuroscience, oncology, respiratory and inflammation, and infection worldwide. Its primary products include Arimidex for hormonal breast cancer; Crestor that provides treatment for managing cholesterol levels; Nexium for acid-related diseases; Seroquel, an atypical anti-psychotic therapy for treating schizophrenia and bipolar mania; and Symbicort for the treatment of asthma in patients. The company also engages in the research, development, manufacture, and marketing of medical devices and implants for use in urology, surgery, and odontology. In addition, it develops and manages hospital-based outpatient cancer centers in the United States; and produces individually adapted abutments for dental implants using a patented CAD/CAM method. The company markets its products to primary care and specialist physicians, as well as to other healthcare professionals, governments, and healthcare buying groups through sales and marketing network, local marketing companies, distributors, and local representative offices. It has collaboration agreements with Bristol-Myers Squibb Company; POZEN Inc.; Abbott laboratories; Columbia University and Newcastle University; Palatin Technologies, Inc; BioDuro Inc.; Jubilant Organosys Ltd.; Merck & Co. Inc.; Cancer Research Technology Limited; Institute of Cancer Research; Alcon Inc.; and Mental Health Research Institute. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca plc in April 1999. AstraZeneca plc was founded in 1992 and is headquartered in London, the United Kingdom.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 44.94 |
| Volume | (mio) 1.18 |
| Volume Avg | (mio) 1.39 |
| 52 Week High | 52.54 |
| 52 Week Low | 40.89 |
| PE | 6.24 |
| PE (group average) | 39 |
| EPS Year | 7.30 |
| EPS change Q/Q | 5.56% |
| EPS change Q/Q Yr ago | 6.54% |
| EPS change Q/Q next Q est | -19.15% |
| EPS change Y/Y | -7.16% |
| REV change Q/Q | 14.29% |
| REV change Q/Q Yr ago | 0% |
| EPS next Q est | 1.41 |
| EPS next Y est | 6.36 |
| Divident Annual | 2.80 |
| Dividend Yield | 6.23% |